Aquis Stock Exchange Weekly Highlights 27/10/23

SulNOx Group PLC announced that its drop-in fuel conditioner, SulNOxEco™, has been verified to have reduced fuel consumption by over 5% in a recent ocean trial in a two-stroke engine burning Marine Diesel Oil (DIN ISO 8217). The company says that during a five month-long trial in cooperation with a Hamburg-based shipping company and a Northern German university for maritime shipping, baseline measurements of fuel consumption on the two-stroke MAN B&W 6S35MC engine were taken at 60% and 70% engine load, before and after using SulNOxEco™ treated fuel. The evaluation measured a consistent 5-6% reduction in specific fuel consumption under real operating conditions during commercial voyages in the North Atlantic Ocean and Mediterranean Sea. Read more…

Quantum Exponential Group plc announced that its CEO, Steven Metcalfe, visited No.10 Downing Street on Thursday 19th October for a critical discussion regarding the future of quantum computing and its transformative impact on the technology landscape. The event, hosted by senior government officials, included Members of Parliament Dominic Johnson, George Freeman, and Professor Julia Sutcliffe, alongside Johnathan Legh-Smith, the head of the UK Quantum. The company stated it was honoured to be part of this discussion, reaffirming its commitment to advancing quantum computing and its active involvement in shaping the future of this groundbreaking industry. The Company added that the invitation to this event followed its recent recognition by the UK Government's Department for Science, Innovation and Technology (DSIT) which awarded Quantum Exponential a six-month paid-for consulting contract in collaboration with Anchored In, to explore strategies for boosting private investment in the quantum sector. Read more…

One Health Group PLC provided the following trading update for the six months to 30 September 2023.
• Financial results for the first six months to 30 September 2023 are expected to be in line with expectations, with the second half of the year historically being the predominant period for surgical activity.
• Revenue for the first half of the year was more than £11 million being an increase of more than 12% on the prior year (H1 2022/23: £9.8m)
• Cash at the half year end of £3.6m (H1 2022/23: £2.7m) provides substantial resources for continuing investment in growth, with operating cash generation underpinning the Group's progressive dividend policy.
• An increase of 12% in new patient referrals compared to H1 2022/23, sourced from Patient Choice through NHS e-Referrals (e-RS), NHS Trust waiting list transfers and direct referrals from NHS Trusts.
• 15 new clinicians joined the Group to support growth in new and existing geographical areas, an increase of 19%.
• Additional surgical theatre capacity brought onstream at existing locations and new capacity secured at a facility in North Yorkshire.
• The Group continues to work closely with NHS Trusts, with two new contracts awarded during H1 to deliver waiting list reduction and direct referrals.
• Following pre-application consultations, a full planning application will be submitted early in H2 for a new surgical hub which will deliver additional operating capacity in 2025. Further locations are being actively pursued.
Read more…

Ananda Developments PLC provided an update on operations alongside its interim results for the period from 1 February 2023 to 31 July 2023. The company focused on two main areas during this time: its wholly-owned subsidiary, DJT Plants Limited ("DJT"), and its 100% owned subsidiary, MRX Medical Limited ("MRX Medical").

MRX Medical has developed a proprietary method to formulate cannabis medicines and three proprietary cannabidiol ("CBD") based formulations. MRX1, MRX Medical's first product, is to be used in two Phase II Randomised Controlled Trials ("RCTs") to investigate the effectiveness of CBD in chemotherapy induced peripheral neuropathy ("CIPN") and in patients with endometriosis. The endometriosis trial is to be funded by the Chief Scientist Office of NHS Scotland via a £300,000 non-dilutive grant, after the reporting period. The CIPN trial has also received combined commitments of £1.25 million in external grant funding and both trials are to be carried out by leading investigators at the University of Edinburgh.

During the reporting period, work continued as DJT refined and progressed its genetic stabilisation programme through to its third generation, collecting 29,000 seeds across 45 genetic lines. DJT now believes it has developed a set of protocols to successfully self-pollinate cannabis and produce enough viable seeds to grow the next generation of plants, each generation of which will be more genetically homogenous than the previous one. This is a significant achievement for a company like DJT and one that the Directors believe will enable DJT to claim IP (Intellectual Property) protections over the unique strains it is breeding.
Read more…

Mydecine Innovations Group Inc. provided a general update on the Company's progress. Josh Bartch, CEO and Chairman of the Company stated, "We have been working diligently over the last few years which have been extremely difficult for the entire industry and our company. Through adversity, Mydecine has become a more robust, well-managed, streamlined, efficient, and productive organisation with a high likelihood of success. Recently, the industry has witnessed several strong catalysts that we believe provide a glimpse into the future, such as large successful financings with very notable participants, open market buys by notable investors such as Steve Cohen, MAPS publishing their second and final phase 3 with incredibly strong results and gearing up for FDA approval in early 2024, Mindset Pharma being acquired by Otsuka, and many others." Read more…